Peptic Ulcer Disease Management

Patient Assessment and Risk Stratification

The American College of Gastroenterology recommends that age, sex, and occupation be considered critical for risk stratification, as older age is a major risk factor for NSAID-related complications 1, 2
Low-dose aspirin, even 75 mg daily, doubles upper GI bleeding risk, according to the American Heart Association 3, 4
The use of antiplatelet agents, such as clopidogrel, increases the risk of bleeding, as stated by the American College of Cardiology 5
Anticoagulants, such as warfarin, substantially increase the risk of bleeding, according to the American College of Gastroenterology 1, 2
Corticosteroids have a synergistic risk with NSAIDs, increasing the risk of bleeding, as reported by the American College of Rheumatology 1, 2

The American College of Gastroenterology states that H. pylori infection increases NSAID-related complications 2-4 fold 2, 6
Eradication of H. pylori reduces ulcer risk from 26% to 7% when starting NSAIDs, according to the American College of Gastroenterology 7, 8

A history of peptic ulcer is the single strongest risk factor, with a 50-100% recurrence rate within one year if H. pylori-related, as stated by the American College of Gastroenterology 9, 4
Previous ulcer complications, such as bleeding, perforation, or obstruction, increase the risk of recurrence, according to the American College of Gastroenterology 3, 10, 8

The American College of Gastroenterology recommends testing and eradicating H. pylori to reduce ulcer likelihood by one-half in NSAID users 6
The use of PPI prophylaxis reduces ulcer recurrence by 60-80%, as stated by the American College of Gastroenterology 6
The American Heart Association recommends low-dose aspirin (75-81 mg) plus PPI to reduce ulcer risk to near-baseline levels 5
The American College of Cardiology states that combination of aspirin 80-100 mg plus esomeprazole 20 mg twice daily is superior to clopidogrel alone in reducing recurrent bleeding 5

Patients with a history of H. pylori-related ulcers have a 50-100% recurrence rate within one year, regardless of PPI use or NSAID exposure, according to the American Gastroenterological Association 11, 12, 13
If H. pylori was never eradicated, the infection persists independently of acid suppression and continues to cause ulceration at approximately 1% per year in those with latent infection, as stated by the American College of Gastroenterology 11, 12
Patients with prior H. pylori ulcer complications face an extraordinarily high risk of 12-36% per year for new ulcer complications, even without NSAID exposure, as reported by the European Helicobacter Study Group 11, 13
In patients with prior ulcer bleeding, the recurrence rate was 9.8% per year with celecoxib alone and 12.8% per year with omeprazole plus diclofenac—neither strategy was sufficiently protective, according to the American College of Gastroenterology 11

Long-term PPI therapy does not address the underlying pathophysiology of H. pylori infection or NSAID-induced mucosal injury, as noted by the American Gastroenterological Association 11, 12

Never assume PPI therapy alone is sufficient protection in patients with prior H. pylori ulcers or ongoing NSAID use, as warned by the American College of Gastroenterology 11, 12
H. pylori eradication is mandatory before starting NSAID treatment in patients with peptic ulcer history, as recommended by the European Helicobacter Study Group 14
In patients with prior ulcer bleeding who require aspirin, H. pylori eradication reduces the residual bleeding risk to very low levels, but PPI co-therapy is still recommended, according to the American Heart Association and the American College of Gastroenterology 14